An in vitro assessment of the approach was done using siRNA transfection in a panel of three EGFR overexpressing GBM lines, including two PTEN mutant lines (U251MG and U118MG) and one PTEN-wild type line (LN229). The gene discussed is EGFR; the disease is glioblastoma.